Welcome to our dedicated page for Lifeloc Technologies news (Ticker: LCTC), a resource for investors and traders seeking the latest updates and insights on Lifeloc Technologies stock.
Lifeloc Technologies, Inc. (LCTC) generates a steady stream of news around its work in breath alcohol testing and drug-of-abuse detection. As a U.S.-based manufacturer of evidential breath alcohol testers and related training and supplies for workplace, law enforcement, corrections and international customers, the company regularly issues updates on financial performance, product development and corporate transactions.
News coverage for Lifeloc often includes quarterly and annual results, where the company discusses revenue trends, gross margins and the impact of research and development spending, particularly related to its SpinDetect/SpinDx centrifugal drug analyzer platform. These releases explain how investment in microfluidic “lab-on-a-disk” technology affects operating results and outline the company’s priorities in advancing rapid, on-site drug testing.
Another major theme in Lifeloc’s news is product innovation. The company has announced live demonstrations and beta testing of its SpinDetect/SpinDx oral-fluid drug analyzer, including reports of laboratory validation against LCMS methods and the ability to detect substances such as delta-9-THC, cocaine, fentanyl, amphetamine, methamphetamine, morphine, MDMA and benzodiazepines. News items also highlight enhancements to L-series LX9 and LT7 breath alcohol devices, such as smart phone pairing, wider temperature ranges and localization features.
Lifeloc’s press releases additionally cover financing and strategic developments, including subordinated debenture financings, private placements, a line of credit, and an Agreement and Plan of Merger with Electronic Systems Technology, Inc. Investors and observers who follow LCTC news can track how these events relate to the company’s efforts to commercialize SpinDetect/SpinDx and support its installed base of breath alcohol testing equipment. For ongoing insight into Lifeloc’s operations, product roadmap and capital strategy, this news feed provides a consolidated view of its publicly released information.
Lifeloc Technologies (OTC: LCTC) reported third-quarter financial results for 2021, showcasing a 21% revenue increase to $1.887 million and net income of $523 thousand ($0.21 per diluted share). This contrasts with Q3 2020, which had revenues of $1.555 million and a net loss of $(213) thousand. The first nine months of 2021 yielded $5.427 million in revenue and a net income of $816 thousand, bolstered by PPP loan forgiveness totaling $936 thousand. The company is optimistic about new product launches, particularly the LX9 and LT7 devices, poised to meet modern market needs, as well as the upcoming R.A.D.A.R. 200 device and SpinDx platform.
Lifeloc Technologies, Inc. (OTC: LCTC) reported its second quarter financial results for 2021, showing a net revenue of $1.730 million and a net loss of $(110) thousand, an improvement from a loss of $(350) thousand in Q2 2020. Revenue increased 31% year-over-year as demand recovers post-COVID-19. For the first six months, net revenue was $3.539 million with a net profit of $294 thousand, aided by a forgivable SBA PPP loan of $465 thousand. Lifeloc is focusing on growth opportunities through new product developments, including the LX9 and LT7 devices.
Lifeloc Technologies (OTC: LCTC) reported Q1 2021 net revenue of $1.810 million with a net income of $403 thousand, or $0.16 per diluted share. This marks a 10% decline in revenue compared to Q1 2020 due to the COVID-19 pandemic. The company received and successfully applied for forgiveness on a $465 thousand SBA PPP loan, and also secured a second loan of $471 thousand. The new L-series products, certified to SAI's standards, are driving market penetration. Lifeloc is focused on developing the SpinDx™ technology and expanding its monitoring and drug detection capabilities.
Lifeloc Technologies (OTC: LCTC) reported its 2020 financial results, revealing a net revenue of $6.357 million, down 27% from 2019's $8.752 million. The company incurred a net loss of $922,000, or $0.38 per diluted share, attributed to the impacts of the COVID-19 pandemic. Despite challenges, Lifeloc received $465,000 in PPP loan forgiveness and launched new products like the LX9 and LT7 devices. The company aims to prioritize the commercialization of the SpinDx technology, enhancing its portfolio in alcohol and drug detection.